In fact, a tau oligomer-specific antibody, T22, has recently been engineered in our laboratory and used in a study that supported the premise of oligomers as therapeutic targets in tauopathies (Lasagna-Reeves et al., 2012a). Here, MAPT is linked to tauopathy.